Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia.
Walter J. Urba(Providence Portland Medical Center), Dan L. Longo(Harvard University), Michael Baseler(Frederick National Laboratory for Cancer Research), John W. Smith(SUNY Upstate Medical University), D Coggin(Frederick National Laboratory for Cancer Research), Jeffrey W. Clark(Massachusetts General Hospital), Ronald G. Steis, William C. Kopp(Frederick National Laboratory for Cancer Research)
PubMed
January 1, 1989
Cited by 108
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k